Abstract:This narrative review appaises the current pharmacological options for the treatment of obesity, with an emphasis on medications directed at incretin and hormonal receptors. These have experienced increased popularity. Direct and indirect mechanisms of action, efficacy, side effect profiles, and use in clinical practice are discussed. Future directions should optimize patient selection to maximize efficacy and minimize adverse effects. Summary Background Obesity has reached epidemic proportions, with >40% of the US population affected. Although traditionally managed by lifestyle modification, and less frequently by bariatric therapies, there are significant pharmacological advancements. Aims To conduct a narrative review of the neurohormonal and physiological understanding of weight gain and obesity, and the development, clinical testing, indications, expected clinical outcomes, and associated risks of current FDA‐approved and upcoming anti‐obesity medications (AOMs). Methods We conducted a comprehensive review in PubMed for articles on pathophysiology and complications of obesity, including terms 'neurohormonal', 'obesity', 'incretin', and 'weight loss'. Next, we searched for clinical trial data of all FDA‐approved AOMs, including both the generic and trade names of orlistat, phentermine/topiramate, bupropion/naltrexone, liraglutide, and semaglutide. Additional searches were conducted for tirzepatide and retatrutide ‐ medications expecting regulatory approval. Searches included combinations of terms related to mechanism of action, indications, side effects, risks, and future directions. Results We reviewed the pathophysiology of obesity, including specific role of incretins and glucagon. Clinical data supporting the use of various FDA‐approved medications for weight loss are presented, including placebo‐controlled or, when available, head‐to‐head trials. Beneficial metabolic effects, including impact on liver disease, adverse effects and risks of medications are discussed, including altered gastrointestinal motility and risk for periprocedural aspiration. Conclusion AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks. Further pharmacological options, such as dual and triple incretins, are probable forthcoming additions to clinical practice for combating obesity and its metabolic consequences such as metabolic dysfunction‐associated steatotic liver disease.

Therapeutic advances in obesity management: an overview of the therapeutic interventions

Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management

New insights into the treatment of obesity.

Contemporary medical, device, and surgical therapies for obesity in adults

Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care

Drug Therapy in Obesity: A Review of Current and Emerging Treatments

Pharmacologic management of obesity: Updates on approved medications, indications and risks

Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Potential therapies for obesity management: Exploring novel frontiers

Evolving Approaches for Pharmacological Therapy of Obesity

Updates in pharmacotherapy of obesity

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

Latest approaches for the treatment of obesity

How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center

Obesity medications: A narrative review of current and emerging agents

Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

Weight Loss Pharmacotherapy: Current and Future Therapies

Effectiveness and safety of drugs for obesity

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients